Browsing Tag
NVO
3 posts
FDA approves Lilly’s Foundayo as second oral GLP-1 weight loss pill, challenging Novo Nordisk’s head start
FDA approves Eli Lilly's Foundayo (orforglipron), the second oral GLP-1 obesity pill with no food restrictions. What this means for LLY investors and patients. Read more.
Novo Nordisk’s amycretin delivers 14.5% weight loss in type 2 diabetes trial: A dual-agonist breakthrough?
Novo Nordisk’s amycretin delivers up to 14.5% weight loss in type 2 diabetes trial. Explore the trial data and what’s next in the GLP‑1 drug race.
Novo Nordisk’s Alzheimer’s treatment hopes crash as semaglutide fails to slow cognitive decline
Novo Nordisk’s GLP-1 pill failed in Alzheimer’s trials, raising questions on neurology diversification. Read what this means for its pipeline and stock.